Dr. Reddy’s Laboratories (RDY) to Release Earnings on Tuesday

Dr. Reddy’s Laboratories (NYSE:RDY) is expected to release its Q4 25/26 results before the market opens on Tuesday, May 12th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.09 per share and revenue of $886.5750 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 25/26 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 10:00 AM ET.

Dr. Reddy’s Laboratories Stock Down 0.8%

NYSE RDY traded down $0.10 during mid-day trading on Tuesday, reaching $13.25. 70,381 shares of the company’s stock traded hands, compared to its average volume of 2,140,822. Dr. Reddy’s Laboratories has a 1-year low of $12.77 and a 1-year high of $16.17. The company has a fifty day simple moving average of $13.80 and a 200-day simple moving average of $13.86. The company has a current ratio of 1.88, a quick ratio of 1.38 and a debt-to-equity ratio of 0.03. The company has a market cap of $11.06 billion, a price-to-earnings ratio of 17.19, a P/E/G ratio of 21.31 and a beta of 0.27.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RDY. Weiss Ratings upgraded Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, April 27th. The Goldman Sachs Group lowered Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, April 23rd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.90.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its position in shares of Dr. Reddy’s Laboratories by 803.8% in the 4th quarter. Russell Investments Group Ltd. now owns 3,091 shares of the company’s stock worth $43,000 after acquiring an additional 2,749 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Dr. Reddy’s Laboratories by 71.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after acquiring an additional 1,294 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Dr. Reddy’s Laboratories in the 4th quarter worth approximately $66,000. Raymond James Financial Inc. acquired a new position in shares of Dr. Reddy’s Laboratories in the 2nd quarter worth approximately $67,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Dr. Reddy’s Laboratories in the 3rd quarter worth approximately $78,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India?based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost?effective generic treatments for branded drugs that have lost patent protection, along with in?house research into innovative molecule development.